Home > Compound List > Product Information
Ethinamate_Molecular_structure_CAS_126-52-3)
Click picture or here to close

Ethinamate

Catalog No. DB01031 Name DrugBank
CAS Number 126-52-3 Website http://www.ualberta.ca/
M. F. C9H13NO2 Telephone (780) 492-3111
M. W. 167.20502 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 903

SYNONYMS

IUPAC name
1-ethynylcyclohexyl carbamate
IUPAC Traditional name
ethinamate
Brand Name
Valaminettae
Valmid
Valmidate
Volamin
Valamin
Valaminetten
Synonyms
Ethinamat
Ethinimate
USAF EL-42
Etinamate

DATABASE IDS

CAS Number 126-52-3
PubChem SID 46507468
PubChem CID 3284

PROPERTIES

Hydrophobicity(logP) 1.2
Solubility 2500 mg/L

DETAILS

Description (English)
Item Information
Drug Groups illicit; approved
Description Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates.
Indication Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents.
Pharmacology Ethinamate is used to treat insomnia (trouble in sleeping). However, it has generally been replaced by other medicines for the treatment of insomnia. If ethinamate is used regularly (for example, every day) to help produce sleep, it is usually not effective for more than 7 days. Structurally, it does not resemble the barbiturates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates. Continued and inappropriate use of ethinamate can lead to tolerance and physical dependence, with withdrawal symptoms very similar to those of the barbiturates.
Toxicity Symptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Absorption Rapidly absorbed following oral administration.
Half Life 2.5 hours
External Links
Wikipedia

REFERENCES